Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 326

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 326
---
 |   |     |              | (2,000,000 | ) |     |             | -           |   |     |       |           - |   |
| Issuance                                                                
 of common shares to Keystone Capital LLC for equity line of credit      |     |                 |      - |     |        |         - |     |        |   1,191 |   |     |        |  - |   |     |            |    633,345 |   |     |              | -          |   |     |             | -           |   |     |       |     633,345 |   |
| Opening                                                                 
 Equity at February 14, 2024 (Successor)                                 |     |                 | 10,039 |     | $      | 8,937,852 |     |        | 145,318 |   |     | $      | 15 |   |     | $          | 53,899,871 |   |     | $            | (2,000,000 | ) |     | $           | (63,185,641 | ) |     | $     |  (2,347,903 | ) |

<div align='center'>F-9</div>

Going concern – The accompanying
unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern,
which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company’s ability
to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (“R&D”)
activities and meet its obligations on a timely basis. As of September 30, 2024, the Company reported $3.4 million of cash, restricted
cash and cash equivalents, with an accumulated deficit of $71.6 million. Additional funds are necessary to maintain current operations
and to continue R&D activities. The Company expects to seek additional funding in the form of equity financings or debt, however,
there can be no assurance that sufficient funding will be available to allow the Company to successfully continue its R&D activities
and planned regulatory filings with the FDA. If the Company is unable to obtain necessary funds, significant reductions in spending and
the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company’s
business, results of operations, and prospects. These conditions raise substantial doubt about the Company’s ability to continue